

# 1 **Prioritizing disease-causing metabolic genes by integrating metabolomics** 2 **with whole exome sequencing data**

3  
4 Michiel Bongaerts<sup>1\*</sup>, Ramon Bonte<sup>1</sup>, Serwet Demirdas<sup>1</sup>, Hidde Huidekoper<sup>2</sup>, Janneke  
5 Langendonk<sup>3</sup>, Martina Wilke<sup>1</sup>, Walter de Valk<sup>1</sup>, Henk J. Blom<sup>1</sup>, Marcel J.T. Reinders<sup>4</sup> and George  
6 J. G. Ruijter<sup>1\*</sup>

7  
8 <sup>1</sup> Department of Clinical Genetics, Erasmus Medical Centre, Dr. Molewaterplein 40, 3015 GD Rotterdam,  
9 The Netherlands

10 <sup>2</sup> Department of Pediatrics, Center for Lysosomal and Metabolic Diseases, Erasmus Medical Centre, Dr.  
11 Molewaterplein 40, 3015 GD Rotterdam, The Netherlands

12 <sup>3</sup> Department of Internal Medicine, Center for Lysosomal and Metabolic Diseases, Erasmus Medical  
13 Centre, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands

14 <sup>4</sup> Faculty of Electrical Engineering, Mathematics and Computer Science, TU Delft, Van Mourik  
15 Broekmanweg 6, 2628 XE, Delft, The Netherlands;

16 \* Corresponding authors

17  
18 **Abstract:** The integration of metabolomics data with sequencing data is a key step towards improving the  
19 diagnostic process for finding the disease-causing gene(s) in patients suspected of having an inborn error  
20 of metabolism (IEM). The measured metabolite levels could provide additional phenotypical evidence to  
21 elucidate the degree of pathogenicity for variants found in metabolic genes. We present a computational  
22 approach, called *Reaffect*, that calculates for each reaction in a metabolic pathway a score indicating whether  
23 that reaction is being deficient or not. When calculating this score, *Reaffect* takes multiple factors into  
24 account: the magnitude and sign of alterations in the metabolite levels, the reaction distances between  
25 metabolites and reactions in the pathway, and the biochemical directionality of the reactions. We applied  
26 *Reaffect* to untargeted metabolomics data of 72 patient samples with a known IEM and found that in 80%  
27 of the cases the correct deficient enzyme was ranked within the top 5% of all considered enzyme  
28 deficiencies. Next, we integrated *Reaffect* with *CADD* scores (a measure for variant deleteriousness) and  
29 ranked the potential disease-causing genes of 27 IEM patients. We observed that this integrated approach  
30 significantly improved the prioritization of the disease-causing genes when compared with the two  
31 approaches individually. For 15/27 IEM patients the correct disease-causing gene was ranked within the  
32 top 0.2% of the set of potential disease-causing genes. Together, our findings suggest that metabolomics  
33 data improves the identification of disease-causing genetic variants in patients suffering from IEM.

## 34 **Introduction**

35 DNA sequencing methods such as whole exome sequencing (WES) and whole genome sequencing (WGS)  
36 are powerful techniques to identify the pathogenic genetic variant(s) in patients suspected of a genetic  
37 disease (Pronicka, et al., 2016) (Wright, et al., 2018) (Stavropoulos, et al., 2016). Nevertheless, a single  
38 WES typically generates tens of thousands of variants (Wright, et al., 2018). With the reduced costs for  
39 sequencing, WGS becomes increasingly popular, generating even a few million of variants per patient  
40 (Wright, et al., 2018). Numerous filtering strategies have been developed to reduce the number of variants  
41 which need to be manually inspected. The Combined Annotation Dependent Depletion (*CADD*) score is  
42 widely explored as one of these filtering strategies (Rentzsch, et al., 2018); prioritizing variants such as  
43 single nucleotide variants (SNV), deletions and insertions (InDels) in patients. *CADD* scores employ a  
44 machine learning based approach where 63 conservation - and functional genomic metrics are combined  
45 into a single metric. After various filtering steps, the investigator still needs to evaluate a substantial number  
46 of variants manually. The pathogenicity of these rare or novel variants is often unknown, leading to a  
47 clinically dissatisfactory classification.

48  
49 Functional studies may provide evidence whether a variant of unknown significance should be considered  
50 pathogenic or not. For this purpose, metabolomics is catching more and more interest since it has the  
51 potential to resolve the degree of pathogenicity for genetic variants which are expected to have an effect on  
52 the patient's metabolism, i.e. inborn errors of metabolism (IEM) (Kerkhofs, et al., 2020) (Alaimo, et al.,  
53 2020) (Linck, et al., 2020). Some strategies have already been developed for this purpose; Haijes et al.  
54 applied expert knowledge to develop an algorithm that matches metabolic signatures obtained from  
55 metabolomics with expected metabolic signatures caused by each IEM, thereby ranking potential enzymatic  
56 deficiencies (Haijes, et al., 2020). Similarly, Baumgartner et al. explored the use of classification algorithms  
57 to distinguish multiple IEM based on differences in metabolite levels (Baumgartner, et al., 2004). However,  
58 training such a classifier requires data from multiple patients having the same IEM and since more than a  
59 1000 different IEM exist with an overall birth prevalence of 51 per 100.000 (Waters, et al., 2018) the  
60 creation of large cohorts is challenging, thereby hampering the use of classification algorithms. To  
61 overcome this limitation, Messa et al. explored the use of metabolic networks to simulate IEM specific  
62 metabolic profiles, which they then compared with real IEM profiles using a Siamese neural network to  
63 rank the most probable matching (simulated) IEM (Messa, et al., 2020). Another strategy involves the use  
64 of gene-metabolite sets for which an enrichment score can be calculated to rank potential affected genes  
65 (Kerkhofs, et al., 2020). Similarly, *MetPropagate* (Linck, et al., 2020) uses gene-metabolite set enrichment  
66 scores, but additionally propagates these scores through a protein-protein network to rank potentially  
67 affected genes. The main concern with these approaches is that enrichment scores require (*Z*-score) cutoffs

68 for metabolite levels, potentially excluding subtle aberrations that do not exceed the thresholds. In a  
69 different approach, Pirhaji et al. developed a tool, called *PIUMet*, that integrates metabolomics data with  
70 other omics data (Pirhaji, et al., 2016). *PIUMet* automatically annotates mass spectrometry (MS) features  
71 while inferring disease-associated pathways using a prize-collecting Steiner Forest algorithm. Still, we  
72 believe that most approaches did not fully exploited some crucial interconnected characteristics of IEM,  
73 i.e.: 1) the direction (increased or decreased) and 2) the magnitude of alterations in the metabolite levels,  
74 3) pathway information including the biochemical directionality of reactions, and 4) reaction distances  
75 between metabolites and reactions.

76  
77 To integrate metabolomics in WES, and potentially WGS, analysis, we developed an algorithm, called  
78 *Reafect* (**R**eaction **d**efect). *Reafect* combines information of metabolic pathways from KEGG (Kanehisa,  
79 2000) and the metabolite Z-scores obtained from annotated metabolomics data to calculate a '*deficient*  
80 *reaction score*' for each reaction. Higher scores imply that there is more evidence of that reaction being  
81 deficient and vice versa. Our algorithm differs fundamentally from the approaches mentioned earlier, since  
82 it is solely based on pathway information, and uses the metabolite Z-scores in a continuous fashion without  
83 using cutoff values. *Reafect* furthermore takes the directionality of the reactions and the sign of the Z-scores  
84 into account when calculating the *deficient reaction scores*. We evaluated *Reafect*'s performance on 36  
85 distinct IEM using 72 plasma samples from patients diagnosed with an IEM.

86  
87 Since each reaction is associated with genes coding for the enzyme catalyzing that reaction, we used  
88 *Reafect*'s *deficient reaction scores* in combination with *CADD* scores as an integrated model for prioritizing  
89 potentially disease-causing metabolic genes. To evaluate this approach, we studied 27 IEM patients for  
90 which the pathogenic variant was identified and untargeted metabolomics data was obtained. This  
91 integrated model showed a significant improvement on ranking the correct disease-causing genes when  
92 compared with using solely *Reafect* or *CADD* scores.

93  
94

## 95 **Results**


### 96 **Reafect**

97 An enzymatic deficiency generally leads to a build-up of the reaction substrate(s) and shortages of the  
98 product(s) formed by that reaction. Z-scores obtained from annotated metabolomics (see Methods) can be  
99 used to detect the accumulation of these substrates (i.e. positive Z-scores) as well as shortages of the  
100 products (i.e. negative Z-scores). Although the accumulation and shortage of metabolites occur for the  
101 metabolites directly involved in the deficient reaction, aberrant metabolite levels will also propagate  
102 through a biochemical pathway, leading to changes in metabolite levels that are multiple reaction steps  
103 away from the deficient reaction. We used this dogma to develop an algorithm, called *Reafect*, that  
104 calculates for each reaction in a pathway a score that reflects how deficient that reaction is. We called this  
105 score the *deficient reaction score* or  $S_R$  score (see Methods for details). To calculate this score, *Reafect*  
106 weighs metabolite levels (Z-scores) which are further away from the considered reaction to a lesser extent  
107 than metabolite levels closer to the putative reaction, since we assume that more distant metabolites give  
108 less information about the reaction deficiency. For this purpose, *Reafect* uses a weighted version of the  
109 observed Z-scores, called '*effective Z-scores*', and which are always relative to the considered reaction for  
110 which the *deficient reaction score* is calculated (see Figure 1). The *effective Z-score* is determined by  
111 calculating a total decay factor over a reaction path when going from the metabolite (with Z-score) to that  
112 reaction. The more steps away from the considered reaction, the more the observed Z-score is decayed,  
113 thereby resulting in a lower (absolute) *effective Z-score*. To constrain the number of model parameters, we  
114 used three different decay factors ( $a, b, c$ ) and distinguished five different decay types: 1) a decay factor  $a$   
115 for a metabolite with a positive Z-score taking a step downstream towards the considered reaction, 2) a  
116 decay factor  $b$  for a metabolite with a positive Z-score taking a step upstream towards the considered  
117 reaction, 3) a decay factor  $a$  for a metabolite with a negative Z-score taking a step upstream, 4) a decay  
118 factor  $b$  for a metabolite with a negative Z-score taking a step downstream and 5) a decay factor  $c$  for  
119 reversible reactions (independent of the Z-score sign) taking one step in the direction of the considered  
120 reaction. We want to emphasize that *Reafect* describes reaction paths as a chain of metabolite and reaction  
121 nodes (in a graph) to track all pathway information (see Figure 1). Consequently, a reaction step is either a  
122 step from metabolite to reaction, or from reaction to metabolite. For example, consider a metabolite with a  
123 positive Z-score which takes three downstream steps to get to the considered reaction (Figure 1a,  $m_2$  to  $R_3$ ).  
124 The *effective Z-score* for this metabolite would then be given by the Z-score multiplied by  $a^3$ , thus having  
125 a total decay factor of  $a^3$ . Similarly, if this metabolite had a negative Z-score the total decay factor for this  
126 reaction path would have been  $b^3$ . Obviously, a reaction path could also be more complex, resulting for  
127 example in a total decay factor of  $c^2 b a^2$ . We justify the introduction of  $a$  and  $b$ , by realizing that when  $a > b$

128 the *effective Z-scores* remain relatively high for positive Z-scores located upstream of a deficiency, and the  
129 same holds for negative Z-scores downstream of the deficiency. The values of these decay factors (*a*, *b* and  
130 *c*) are selected using the metabolomics data from 72 IEM patient samples (see Section *Tuning the model*  
131 *parameters*). Subsequently, *Reaffect* aggregates all *effective Z-scores* resulting in the *deficient reaction score*  
132 (or  $S_R$  score) where it takes into account whether a certain *effective Z-score* was located downstream or  
133 upstream of the considered reaction (see Methods, Equation 6).

134 Finally, *Reaffect* prioritizes all reactions by sorting the  $S_R$  scores on their magnitude, with higher scores  
135 indicating that a reaction is more likely to be deficient. Next to prioritizing the reactions, *Reaffect* can  
136 prioritize enzymes and corresponding genes on their potential of being deficient. As enzymes can be  
137 involved in multiple reactions the final  $S_R$  score for an enzyme is taken to be the maximum  $S_R$  score of the  
138 set of reactions the enzyme may catalyze (Method).

139



140  
141 Figure 1. Illustration of *Reaffect*. A circle indicates a metabolite and a square a reaction (node), with the horizontal arrows indicating  
142 the directionality of the reaction. The vertical grey bars (with dot) indicate the observed Z-scores; pointing upwards indicating a  
143 positive Z-score and vice versa. The black dotted bars indicate the *effective Z-score* from the perspective of reaction R<sub>3</sub>. Note that

144 *Reaffect* determines for each reaction a *deficient reaction score* but in these figures only the results are shown for  $R_3$ . **A)** Reaction  
145  $R_3$  is deficient. The *effective Z-scores* decay when going away from  $R_3$  as visualized by the reduced magnitude of the black bars.  
146 The *deficient reaction score*, illustrated by the blue bar on  $R_3$ , is high since we observe net positive *effective Z-scores* upstream of  
147  $R_3$  and net negative *effective Z-scores* downstream of  $R_3$ . **B)**  $R_3$  is not deficient and metabolite *Z-scores* around the reaction are  
148 normal, thereby resulting in a low *deficient reaction score*. Note that the blue bar at  $R_3$  is small. **C)**  $R_3$  is not deficient, but has still  
149 a relatively high *deficient reaction score*. Note that although the observed *Z-scores* for  $m_3$  and  $m_4$  are equal, the resulting *effective*  
150 *Z-scores* are different since the decay of the *Z-scores* also depends on the biochemical directionality (and also applies to  $m_2$  and  
151  $m_5$ ). Metabolite  $m_1$  has a relatively high observed *Z-score*, but its *effective Z-scores* is reduced since it is 5 reaction steps away  
152 from  $R_3$ . *Reaffect* calculates per side of the reaction the net *effective Z-scores*. For example, the *effective Z-scores* for  $m_4$  and  $m_5$   
153 roughly counter balance each other when looking at the downstream side of  $R_3$ . The upstream side has net positive *effective Z-*  
154 *scores*, therefore resulting in a positive *deficient reaction score*.

155

### 156 **Tuning the model parameters**


157 Per IEM patient, potential deficient enzymes were ranked by their maximum associated  $S_R$  score (Methods)  
158 and the rank of the true deficient enzyme in that patient was reported (Figure 4, *Absolute rank*). Since the  
159 total number of enzymes on which the ranking was based varied among the patients, we determined the  
160 percentile rank (PR) by dividing by the total number of enzymes multiplied by 100% (Methods). A lower  
161 PR indicates an improved ranking performance and vice versa. The overall performance of *Reaffect* was  
162 measured by calculating how often a PR was smaller or equal than a predefined value across the 72 IEM  
163 patient samples. When increasing this predefined value a curve is generated as displayed in Figure 3. We  
164 used the area under this curve (AUC) to indicate the overall performance of *Reaffect*, where higher AUCs  
165 imply better performances.

166

167 Since *Reaffect* uses three model parameters ( $a$ ,  $b$ ,  $c$ ), we used a parameter sweep over these parameters to  
168 explore how the performance (AUC) was affected. We performed a bootstrap procedure to obtain a robust  
169 performance AUC (Methods). Figure 2 shows these bootstrapped AUCs for each combination of ( $a$ ,  $b$ ,  $c$ ).  
170 For region  $b > a$ , *Reaffect* performs less than for region  $b < a$ . This can be understood by realizing that when  
171  $a > b$  the *effective Z-scores* for metabolites having positive *Z-scores* decay faster for downstream steps than  
172 for upstream steps (and the opposite for negative *Z-scores*), resulting in reduced evidence for the deficient  
173 reaction. Furthermore, for region  $c < 0.5$ , *Reaffect's* overall performance is poor. The highest performance  
174 was reached for  $a = 0.85$ ,  $b = 0.35$ , and  $c = 0.75$  (see Figure 2B). In further evaluations of *Reaffect*, we set  
175 the parameters  $a$ ,  $b$ ,  $c$  to these values.

176






177  
178 Figure 2. **A)** Bootstrapped AUCs (Methods) for different combinations of *Reaffect*'s hyper parameters ( $a, b, c$ ). The colors indicate  
179 the percentage of the maximum obtained AUC. **B)** Contour plot of the (cubic interpolated) bootstrapped AUCs while fixing  $c=0.75$   
180 and varying  $a$  and  $b$ . The contour levels indicate the percentage of the maximum AUC reached at  $a = 0.85$ ,  $b = 0.35$ ,  $c = 0.75$ .

181  
182 **Enzyme ranking for IEM patients**

183 We applied *Reaffect* to 72 IEM patient samples and determined the percentile rank (PR) of the true enzyme  
184 deficiency. For 61% of these samples the PR was within the top 2.5% of all considered enzyme deficiencies,  
185 and for 80% of the samples the PR was within the top 5% (Figure 3). Additionally, we compared *Reaffect*  
186 with *MetPropagate* (Linck, et al., 2020), while taking several factors into account such as overlapping  
187 metabolites and genes between the two approaches to objectively compare the performances (Methods).  
188 Based on 65 IEM patient samples, we found that *Reaffect* has a 19% increase in the AUC when compared  
189 to *MetPropagate*. Considering that lower percentile ranks (<10%) are more interesting (Figure 3B), we  
190 observe that for this region the partial AUC of *Reaffect* is 69% higher than the partial AUC of *MetPropagate*.  
191 A detailed overview of the PRs per IEM patient for both approaches can be found in Supplement 1.  
192




193

194 Figure 3. IEM ranking performances for different approaches as indicated by the legend. Each curve shows the percentage of IEM  
 195 patient samples for which the percentile rank (PR) of the true enzyme deficiency is within the top  $x$  % (horizontal axis) of all  
 196 considered enzyme deficiencies. Model settings for *Reaffect*:  $a = 0.85$ ,  $b = 0.35$  and  $c = 0.75$ . **A)** Full performance curves. **B)**  
 197 Performance curves with  $PR \leq 10\%$ . To perform a meaningful comparison between *Reaffect* and *MetPropagate* a subset of the  
 198 data was analyzed that contained only metabolites and genes that were included in both approaches (Methods). Note that this  
 199 selection reduced the performance of *Reaffect* to 91% of its original performance.

200

201 Figure 4. shows a detailed overview of the results per IEM patient. From this figure it is clear that for the  
 202 same IEM but different patients, *Reaffect* can return different PRs. For example, one patient with maple  
 203 syrup urine disease (BCKDH) has a PR of 0.36%, whereas for the other patient this is 4.19%. This can be  
 204 explained by the difference in the magnitude of the Z-scores for the disease-related metabolites leucine and  
 205 isoleucine, namely for the patient with the low rank  $Z = 6.7$  and  $Z = 5.4$ , respectively, and for the patient  
 206 with the higher rank these Z-scores were less extreme,  $Z = 2.49$  and  $Z = 2.65$ , respectively. Similarly, for  
 207 two patients having long-chain-3-hydroxyacyl-CoA dehydrogenase deficiency (HADHA), one has a PR of  
 208 0.54% and for the other this is 1.62%. Again, this difference in PRs can be understood by differences in for  
 209 example 3-hydroxyhexadecanoylcarnitine, which had a Z-score of  $Z = 13.3$  for the patient with the lower  
 210 PR, while the other was more subtle with  $Z = 6.4$ . Also, one patient with carbamoyl phosphate synthetase  
 211 I deficiency (CPS1) ranked at 1.73%, had  $Z = 1.8$  for L-glutamine, while the other patient (ranked at  
 212 19.37%) seemed to have a normal L-glutamine level ( $Z = 0.2$ ), thereby explaining also the difference  
 213 between these ranks.





214

215 Figure 4. Detailed overview of the ranks of the correct IEM per patient. The first column indicates the PR (for the known deficient  
 216 enzyme) for a given patient. Blue colors indicate PRs lower than 5%, orange/red colors indicate PRs above 5% (see color bar). The  
 217 second column shows the absolute rank of the deficient enzyme. The third column indicates the total number of the ranks/ unique  
 218 enzymes on which the ranking was based (this number varies across patients due to differences in metabolite annotations). The  
 219 fourth column indicates the number of annotated metabolites in the pathway on which the *deficient reaction score* was based. The  
 220 fifth column shows the total number of metabolites present in that pathway. For the HADHA gene, which encodes two enzymatic  
 221 functions, we selected enzyme EC 1.1.1.211. The patient samples ASS<sub>a</sub> and ASS<sub>b</sub> originate from the same patient, but were acquired  
 222 on different dates. The same holds for the samples IVD<sub>a</sub> and IVD<sub>b</sub>.

223

224 Some IEM were poorly ranked due to the absence of clear aberrations in the metabolomics data. For both  
 225 patients with alkaptonuria (homogentisate 1,2-dioxygenase deficiency, HGD), homogentisic acid was not  
 226 increased in our analysis ( $Z = 0.4$  and  $Z = 0.5$ ), which clarifies why *Reafect* poorly ranked these patients.  
 227 The patient with mevalonate kinase deficiency (MVK) was also ranked poorly, which was a consequence

228 of two reasons: 1) only one metabolite involved in calculating the  $S_R$  score i.e. mevalonic acid, was  
229 annotated in the metabolomics data and 2) the Z-score of this metabolite was  $Z = 0.7$ .

230

231 *Reaffect* ranked the patient with arginase I deficiency (ARG1) at 0.36%. This was considered to be a  
232 relatively good ranking, since 14 metabolites were found to have a Z-score above 2.1, while the disease  
233 related metabolites arginine and ornithine had  $Z=2.1$  and  $Z= -2.4$  respectively. From a naive perspective  
234 we would expect about 14 other enzyme deficiencies to have lower (better) rank than arginase I. However,  
235 this relatively good performance can be explained by the fact that arginase I catalyzes the conversion of  
236 arginine into ornithine (plus urea), and the substrate (arginine) is increased while the product (ornithine) is  
237 reduced. Consequently, *Reaffect* assigned a relatively high  $S_R$  score to this reaction. To strengthen this  
238 explanation, we used *Reaffect* while flipping all Z-score signs (positive Z-scores become negative Z-scores  
239 and vice versa), and we observe that for this patient the PR increased from 0.36% to 26.11% (Supplement  
240 2, Figure S3). This demonstrates that the obtained PR (0.36%) was a consequence of taking the Z-score  
241 signs and biochemical directionality into account.

242  
243 Another interesting observation is the poor rank obtained for the patient having guanidinoacetate N-  
244 methyltransferase deficiency (GAMT). This patient was under treatment with creatine supplementation,  
245 which explains the poor rank. Although guanidinoacetate ( $Z = 3.1$ ) was high in this patient, the presence of  
246 the high creatine level ( $Z = 6.7$ ) led to high Z-scores on both sides of the GAMT reaction R01883 which  
247 reduces the  $S_R$  score, as can be observed in Equation 6 (Methods),

248

#### 249 **Gene prioritization for IEM patients using *CADD* scores and *Reaffect***

250 We hypothesized that potentially affected (metabolic) genes could be better prioritized when we combine  
251 the *CADD* (Phred) scores obtained from variants in WES data with the *deficient reaction scores* obtained  
252 from *Reaffect*. Since an increase in both scores is expected to be associated with increased pathogenicity we  
253 chose to multiply the *deficient reaction score* with the maximum *CADD* score observed in the variants of  
254 the gene corresponding to that enzyme. Next, we used this combined score to rank the genes (Methods).

255

256 Since WES data was only available for two IEM patients, we evaluated this gene ranking based on two  
257 approaches: 1) using the WES background belonging to that patient if the WES was available (see asterisks  
258 in Table 1) and 2) using 15 random WES backgrounds while inserting the (known) disease-causing variant  
259 of the patient (Methods). Table 1 shows the PRs for 28 IEM patients for which the pathogenic variant was  
260 identified, using solely *Reaffect*, solely *CADD* scores as well as the integrated approach. For 12/28 patients  
261 *Reaffect* scored better than *CADD* (marked blue). For 21/28 and 20/28 patients, the integrated approach led

262 to improved ranking when compared only to *Reaffect* or *CADD* scores, respectively. Especially the gain in  
 263 ranking performance for patients 5 (ACADV L), 7 (ACAT1), 15 and 16 (GLDC), and 23 (OGDH) is  
 264 noteworthy (marked orange).

265  
 266 Table 1. Overview of the IEM and disease-causing gene ranks for 28 IEM patients using *Reaffect*, *CADD* scores and the integrated  
 267 approach. The first column indicates the patient, second columns the deficient enzyme with EC identifier. The third columns refers  
 268 to the affected gene. Next columns contain the PRs for each method as indicated by the column name; *Reaffect* (only), *CADD* (only),  
 269 and the integrated approach. The approaches using the 15 random WES backgrounds report the mean, minimum and maximum  
 270 obtained PR across the 15 backgrounds. Blue marked results indicate that the PR of *Reaffect* is lower than the PR of *CADD*. Orange  
 271 marked results indicate a clear improvement of the integrated approach over the individual approaches.

272 \* The PR for *CADD* was 0.24% using the real WES, and 0.0% for *Reaffect with CADD* using the real WES.

273 \*\* The PR for *CADD* was 0.58% using the real WES, and 0.35% for *Reaffect with CADD* using the real WES.

274

Patient	Enzyme	Gene	Reaffect Percentile rank (%)	CADD Percentile rank (%)	Reaffect with CADD Percentile rank (%)
				mean [min, max]  15 random WES backgrounds	mean [min, max]  15 random WES backgrounds
Patient 1	1.3.8.7	ACADM	1.71	0.4 [0.12,0.59]	0.0 [0.0,0.0]
Patient 2	1.3.8.7	ACADM	0.51	6.04 [5.33,7.16]	0.25 [0.11,0.36]
Patient 3	1.3.8.7	ACADM	3.59	0.41 [0.12,0.59]	0.11 [0.0,0.12]
Patient 4	1.3.8.7	ACADM	1.53	0.45 [0.12,0.64]	0.04 [0.0,0.12]
Patient 5	1.3.8.9	ACADV L	1.42	3.2 [1.85,4.22]	0.3 [0.12,0.5]
Patient 6	1.3.8.9	ACADV L	0.18	1.57 [1.03,2.07]	0.06 [0.0,0.24]
Patient 7	2.3.1.9	ACAT1	1.11	2.47 [1.33,3.52]	0.36 [0.24,0.62]
Patient 8	2.3.1.9	ACAT1	1.24	0.06 [0.0,0.23]	0.01 [0.0,0.12]
Patient 9	4.3.2.1	ASL	2.93	1.88 [1.19,2.6]	2.29 [2.02,2.59]
Patient 10	2.3.1.21	CPT2	9.01	0.73 [0.35,1.3]	4.3 [3.53,4.87]
Patient 11	2.3.1.21	CPT2	0	4.05 [2.78,5.15]	0.12 [0.0,0.25]
Patient 12	3.7.1.2	FAH	4.64	4.06 [2.41,5.38]	5.02 [4.48,5.59]
Patient 13	2.1.1.2	GAMT	28.99	0.05 [0.0,0.13]	5.26 [4.33,6.34]
Patient 14	1.3.8.6	GCDH	0.53	0.35 [0.11,0.59]	0.18 [0.0,0.46]
Patient 15	1.4.4.2	GLDC	4.09	2.26 [1.28,3.0]	0.64 [0.35,0.94]
Patient 16	1.4.4.2	GLDC	2.86	2.4 [1.31,3.17]	0.39 [0.11,0.66]
Patient 17	1.1.1.211	HADHA	0.54	1.04 [0.63,1.59]	0.11 [0.0,0.25]
Patient 17	4.2.1.17	HADHA	0.18	1.04 [0.63,1.59]	0.11 [0.0,0.25]
Patient 18*	3.2.1.25	MANBA	0	0.42 [0.12,0.71]	0.0* [0.0,0.0]
Patient 19	6.4.1.4	MCCC2	0	7.0 [6.11,8.31]	0.04 [0.0,0.12]
Patient 20	5.4.99.2	MMUT	7.89	0.83 [0.35,1.42]	0.99 [0.46,1.27]
Patient 21	1.5.1.20	MTHFR	3.03	0.53 [0.12,0.97]	0.63 [0.35,0.93]
Patient 22	2.7.1.36	MVK	31.89	0.67 [0.35,1.3]	10.86 [9.78,11.59]
Patient 23	1.2.4.2	OGDH	1.83	8.04 [2.71,9.91]	0.13 [0.0,0.35]
Patient 24	2.1.3.3	OTC	6.7	0.51 [0.12,0.84]	1.32 [0.82,1.64]
Patient 25	1.14.16.1	PAH	0.18	2.08 [1.27,2.65]	0.0 [0.0,0.0]
Patient 26	1.14.16.1	PAH	0	1.22 [0.75,1.71]	0.0 [0.0,0.0]
Patient 27**	1.2.4.1	PDHA1	3.92	0.65 [0.34,1.09]	0.17 [0.11,0.36]
Patient 28	2.4.2.4	TYMP	0	0.46 [0.23,0.73]	0.0 [0.0,0.0]


275

276 To explore the overall differences in ranking performances between the three methods, we plotted the PRs  
 277 in a boxplot (Figure 5). We removed the patient with guanidinoacetate N-methyltransferase deficiency from  
 278 this analysis, arguing that the metabolic profile of this patient was not representative for this IEM because

279 of the treatment. Using the Mann-Whitney U test, we observe that the performance between *Reafect* and  
280 *CADD* did not significantly differ ( $p\text{-value} > 0.05$ ). However, the integrated approach significantly  
281 (Wilcoxon signed-rank test,  $p\text{-value} < 0.05$ ) improved the ranking performance when compared with solely  
282 using *Reafect* or *CADD* scores. In other words, by combining the two scores we gained improved IEM  
283 ranking/ gene prioritization.

284

285



286

287

288 Figure 5. Boxplots of the percentile ranks (PRs) obtained from the different approaches; *Reafect* (only), *CADD* (only), and the  
289 integrated approach. For *CADD* and the integrated approach we used the average PR obtained from the 15 random WES.  
290 Significance was determined using the Wilcoxon signed-rank test (WSR) when comparing *Reafect with CADD* with *CADD* or  
291 *Reafect*. We used the Mann-Whitney U test (MWU) for comparing *CADD* with *Reafect*, arguing that the PRs for *CADD* and *Reafect*  
292 are independent since they are obtained from two separate datasets and approaches.

293

## 294 Discussion

295 Our aim was to use metabolomics data as additional evidence for filtering genetic variants found in WES  
296 data. For this purpose, we developed *Reaffect*, an algorithm that scores the efficacy of each reaction in a  
297 pathway. To calculate these scores, *Reaffect* combines four types of information: 1) the magnitude and 2)  
298 sign of the metabolite Z-scores, 3) the biochemical directionality of reactions, and 4) the reaction distances  
299 between the metabolites and a reactions in a pathway. We observed that *Reaffect* ranked the true deficient  
300 enzyme for 80% of the 72 IEM patient samples within the top 5% of all considered enzyme deficiencies.  
301 *Reaffect* showed improved ranking performance when compared to *MetPropagate*. We anticipate that this  
302 improvement may at least partially be explained by three differences between *Reaffect* and *MetPropagate*.  
303 First, since *MetPropagate* uses cutoff values for the metabolite Z-scores when calculating the enrichment  
304 scores, we expect relevant but subtle aberrant metabolites to be neglected. *Reaffect* uses the Z-scores in a  
305 continuous fashion, therefore even subtle aberrations contribute to the *deficient reaction scores* and  
306 positively impact IEM ranking (see Supplement 6). Secondly, metabolite-gene set enrichment approaches  
307 only consider metabolites which have a direct relationship with a gene, such as well-known biomarkers.  
308 Metabolite levels which are multiple reaction steps away from the deficiency may still be informative but  
309 will not contribute to the enrichment score when these metabolites are not included in the metabolite-gene  
310 set. Thirdly, *MetPropagate*, and approaches like the ones suggested by Pirhaji et al. and Kerkhofs et al., do  
311 not explicitly take the directionality of reactions and the sign of metabolite levels (decreased/increased) into  
312 account. We showed that *Reaffect*'s IEM ranking performance was greatly reduced by flipping the sign of  
313 the metabolite Z-scores (Supplement 2), emphasizing that the Z-score sign and reaction directionality are  
314 important for *Reaffect*. We furthermore showed that by choosing optimal values for our model parameters  
315 ( $a, b, c$ ), we were able to improve the IEM ranking performance. Since these model parameters relate to the  
316 interaction of the Z-score signs with reaction directionality, this again confirms that including this  
317 information is valuable.

318  
319 Integration of metabolomics with WES was achieved by multiplying the maximum *deficient reaction scores*  
320 with the maximum *CADD* score found for each enzyme and corresponding gene respectively (Methods).  
321 This integrated approach resulted in a significant improvement of ranking the true disease-causing genes  
322 (see Figure 5), where the median percentile rank (PR) was 1.36% lower than the median PR obtained from  
323 *Reaffect*, and was 0.87% lower than the median PR obtained from using solely *CADD* scores.

324  
325 In reality the human metabolome is one interconnected network of metabolites and reactions. In this study  
326 we have chosen to use isolated metabolic modules/pathways for two reasons. First, the (KEGG) pathways

327 are clusters of highly interdependent reactions, for which we expect multiple metabolite levels to be affected  
328 if a pathway contains an enzymatic deficiency. Secondly, the direct use of a complete metabolic network  
329 would introduce metabolic ‘hubs’ that would connect more distinct parts of the metabolism. This  
330 entanglement of pathways/reactions may have unwanted consequences for the *deficient reaction scores*  
331 since also less relevant metabolite Z-scores would be involved in the calculation of these scores. A negative  
332 consequence of using isolated modules/pathways might be that some important reactions are not included.  
333 Although the goal was to develop an algorithm with minimum manual adjustments, we needed to add  
334 several reactions, such as glycine conjugation and carnitine esterification, to increase the overlap between  
335 metabolites measured in plasma and the metabolites included in the pathways (Supplement 4).

336  
337 *Reaffect* also has some limitations. First, if not all metabolites in the KEGG pathway are measured and  
338 annotated, this may lead to wrong conclusions. A single metabolite with a relatively high Z-score will cause  
339 all (downstream) reactions to have high *deficient reaction scores*. The inclusion of more measured  
340 metabolites could prevent this behavior, since metabolite Z-scores with the same sign on both sides of the  
341 reaction reduce the *deficient reaction score* (Methods, Equation 6). The IEM ranking performance of  
342 *Reaffect* is therefore affected by the number of metabolites being measured within each pathway. Secondly,  
343 *Reaffect* is based on the assumption that IEM have the signature where substrates of the deficient reaction  
344 become more abundant and the products decrease in abundance. In case such signature does not hold for a  
345 certain IEM, we expect *Reaffect* to detect these kinds of IEM poorly. At last, *Reaffect* ignores  
346 compartmentalization of different metabolic processes. A substantial number of metabolic reactions occur  
347 within certain compartments of the cell such as the mitochondrion. Similarly, different organs contain  
348 different sets of metabolic reactions, therefore the concentration of the affected metabolites for an IEM may  
349 be very different from the concentrations measured in plasma on which our Z-scores are based.

350  
351 For most IEM patients with an identified disease-causing variant in this study, the putative gene was directly  
352 sequenced, and therefore no WES data was obtained. We inserted the identified disease-causing variant in  
353 15 random WES backgrounds, to enable the inclusion of these patients in our study. We assumed that the  
354 average ranking obtained from these 15 backgrounds was still a good estimate of the ranking which would  
355 have been obtained when the real WES data was used. Due to our limited number of patients with real WES  
356 data (N=2), a reliable comparison between both rankings is not possible, and thus we cannot validate the  
357 accuracy of this assumption. Note that the PRs obtained from the real WES fall within the minimum and  
358 maximum PR obtained from the 15 WES backgrounds (Table 1).

359



360 *Reaffect* uses only three decay factors ( $a$ ,  $b$ ,  $c$ ) which we optimized using an overall performance metric (see  
361 Results, Figure 2). Ideally, these decay factors are optimized using a training set while using a separate  
362 validation set for evaluating the IEM ranking performances. Due to the low number of IEM patients  
363 included in this study we decided to use all samples for optimization and validation, arguing that splitting  
364 the dataset into a training - and validation set would lead to less accurate estimates of the decay factors and  
365 would give less insights into the overall performance of *Reaffect* on distinct IEM. Note that we did use a  
366 bootstrap procedure to prevent overfitting of the decay factors (Methods). To further support our findings,  
367 we separately optimized the decay factors using a subset of the 72 IEM patient samples; the 44 samples for  
368 which the disease-causing variant was unknown. Using the same bootstrap procedure, we obtained an  
369 optimum close to the one found when using all 72 samples (Supplement 5).

370  
371 We realize that the use of three decay factors is a simplification, and that these factors should ideally be  
372 reaction specific. Kinetic parameters, such as the Michaelis–Menten constant, could be used to establish  
373 such reaction dependent decay factor. Currently accurate kinetic parameters are only available for a subset  
374 of reactions. Besides the additional complexity introduced by these reaction specific decay factors, the use  
375 of just three decay factors offered us the opportunity to demonstrate the overall importance of choosing  
376 different decay factors for reaction directionality and the sign of the Z-score, as we clearly observed in  
377 Figure 2. Still, we anticipate that *Reaffect*'s performance on ranking IEM/genes could improve when  
378 reaction specific decay factors are incorporated.

379  
380 *Reaffect* may not only be useful in the context of IEM but could be applicable in a wider context since the  
381 *deficient reaction scores* are a direct readout of potential accumulations and/or reductions of metabolites  
382 before/after a reaction. For example, *Reaffect* is potentially useful in drug screening research for generating  
383 an overview of drug candidates which have the potential to inhibit metabolic enzymes. Namely, we expect  
384 that the inhibition of an enzyme by a drug will result in metabolic signatures similar to the ones caused by  
385 an IEM where the same enzyme is affected.

386  
387 In conclusion, the integration of metabolomics data with WES data by using *Reaffect*'s *deficient reaction*  
388 *scores* and *CADD* scores, significantly improved the prioritization of pathogenic genes in patients suffering  
389 from an IEM.

390

391

## 392 **Method**

393

### 394 **Untargeted metabolomics data and Z-scores**

395 Metabolomics data was obtained as described by Bonte et al. Samples obtained from IEM patients were  
396 measured in 20 separate batches and features were annotated using an in-house database having MS/MS  
397 spectra and retention times of each metabolite (Bonte, et al., 2019). For the 72 patient samples, a median of  
398 119 annotated metabolites was obtained (when combining positive – and negative ion mode), and a  
399 minimum of 95 annotated metabolites was available for each sample. In agreement with national legislation  
400 and institutional guidelines, all patients or their guardians approved the possible anonymous use of the  
401 remainder of their samples for method validation and research purposes. The study was conducted in  
402 accordance with the Declaration of Helsinki. Z-scores were calculated using two different approaches: 1)  
403 metabolites which were annotated in at least 7 batches were merged, a Box-Cox transform was applied,  
404 normalized using *MetChalizer* (Bongaerts, et al., 2020) and the Z-scores were determined using a regression  
405 model with age and sex as covariates (Bongaerts, et al., 2020), 2) for metabolites which were annotated in  
406 less than 7 batches, the Z-scores were determined from 15 within-batch samples, where abundancies were  
407 first Box-Cox transformed and normalized using Probabilistic Quotient Normalization (PQN). When a  
408 metabolite was annotated in both positive- and negative ion mode, the Z-score of the ion mode with the  
409 largest median abundance (over all samples) was taken. Since three technical replicates were measured for  
410 all patient samples, we used the average of these three Z-scores as the final Z-score (which was then  
411 transformed using Equation 1).

412

### 413 **Z-score transformation**

414 To prevent extreme Z-scores to dominate the *deficient reaction scores*, we transformed the Z-score by  
415 applying:


416

$$417 \tilde{Z} = \frac{\text{sign}(Z)}{1 + \exp(2 - |Z|)} [ |Z|^{0.75} - |Z| ] + Z \quad 1)$$

418

419 This transform behaves linear for the region  $0 < |Z| < 2$ , but scales down Z-scores when  $|Z| \gg 2$  (Figure 6).

420



421  
422 Figure 6. The effect of the transformation given by Equation 1 on the Z-scores.

423  
424 **WES data**

425 Whole Exome Sequencing (WES) data was acquired over a longer time period (2013-2021), and was  
426 performed either using the Agilent Clinical Research Exome V1 (sureselect SSCRE V1) or Agilent Clinical  
427 Research Exome V2 (sureselect SSCRE V2) on a *Illumina NovaSeq* sequencer using paired-end reads with  
428 a read-length of 150 bp. Reads were aligned to human reference genome build GRCh37/ hg19  
429 (ucsc.hg19.nohap.fasta) using the BWA alignment algorithm (Li & Durbin, 2009). The VCF-files were  
430 obtained using GATK3 (McKenna, et al., 2010) and ANNOVAR was used to annotate gene names and  
431 variants (Wang, et al., 2010). All patients included in this study from which WES data was used gave  
432 consent for anonymous use of their data for research purposes.

433  
434 **Retrieving human metabolic reactions**

435 We used the KGML parser from <https://github.com/biopython/biopython> (20-03-2020) to process KEGG  
436 (Kanehisa, 2000) pathways and modules, where we filtered on reactions involved in humans (using the *hsa*  
437 pre-fix). When retrieving the KEGG networks, some reactions were associated with more than one enzyme,  
438 for which KEGG returns the same unique reaction as many times as it is associated with the different  
439 enzymes, leading to a multiplicity for these reactions. We removed this multiplicity but we remained all the  
440 associated enzymes with this reaction. In other words, in these cases the same  $S_R$  score for that reaction was  
441 assigned to all associated enzymes.

442  
443 To increase the overlap between the metabolites measured in plasma and metabolites in in the  
444 pathways/modules (from KEGG), we manually added some reactions. These can be found in Supplement  
445 4. Most of these reactions were obtained from Recon / Virtual Metabolic Human (Noronha, et al., 2018).

446 **Reaffect**

447 To determine the *deficient reaction score* for a certain reaction, we first consider the decay of the Z-score  
 448 over a path  $p$  leading for metabolite  $m$  to reaction  $R$ :

449

$$E_{m,R,p}(Z_m) = \left( \prod_s^{\text{steps} \in p} \gamma_s(Z_m, D_s) \right) |Z_m| \quad 2)$$

450

451 Here,  $E_{m,R,p}(Z_m)$  is the *effective Z-score* for metabolite  $m$  from the perspective of reaction  $R$  along reaction  
 452 path  $p$ .  $\gamma_s(Z_m, D_s)$  is the decay factor for step  $s$  and depends on the biochemical directionality of the step  
 453 ( $D_s$ ) (upstream, downstream, reversible) and the sign of the Z-score ( $Z_m$ ):  
 454

455

$$\gamma_s(Z_m, D_s) = \begin{cases} a & \text{if } \text{sgn}(Z_m) = 1 \text{ and } D_s = \text{downstream} \\ a & \text{if } \text{sgn}(Z_m) = -1 \text{ and } D_s = \text{upstream} \\ b & \text{if } \text{sgn}(Z_m) = 1 \text{ and } D_s = \text{upstream} \\ b & \text{if } \text{sgn}(Z_m) = -1 \text{ and } D_s = \text{downstream} \\ c & \text{if } \text{sgn}(Z_m) = 1 \text{ and } D_s = \text{reversible} \\ c & \text{if } \text{sgn}(Z_m) = -1 \text{ and } D_s = \text{reversible} \end{cases} \quad 3)$$

456

457 For irreversible reactions,  $a$  is the decay factor for the Z-score when the sign of the Z-score is positive and  
 458 the reaction step is downstream, or when the Z-score is negative and the reaction step is upstream. The  
 459 parameter  $b$  is the decay factor for the opposite cases; the sign of the Z-score is positive (negative) and the  
 460 reaction step is upstream (downstream). For reversible reactions we introduce parameter  $c$  as decay factor.  
 461 Note that this decay is independent of the sign of the Z-score.  
 462

463

464 Since more paths ( $p$ 's) could be possible between metabolite  $m$  and reaction  $R$ , and these could have  
 465 different lengths, we calculated a normalized *effective Z-score* for every path:

466

$$\tilde{E}_{m,R,p} = \frac{[E_{m,R,p}(Z_m)]^2}{\sum_{p'} |E_{m,R,p'}(Z_m)|} \quad 4)$$

467

468 where  $\tilde{E}_{m,R,p}$  is the *normalized effective Z-score* for path  $p$ . The summation over  $p'$  indicates all paths  
 469 leading from  $m$  to  $R$ . In this way, paths originating from  $m$  with (relatively) low *effective Z-score* strengths  
 470 (such as longer paths) are weighted less in the *normalized effective Z-score* whereas short paths get more  
 471 weight since their *effective Z-score* is relatively large (when compared to the other paths). All paths ( $p$ 's)  
 472

473 were determined by constructing an ‘ego graph’ around each metabolite, selecting a subset of neighboring  
 474 metabolites and reactions around this central metabolite. To reduce computational cost, we set a limit of 15  
 475 reaction steps (metabolite-reaction or reaction-metabolite) around this ego graph, and a maximum of 10  
 476 paths for travelling from  $m$  to  $R$ .

477  
 478 Next, we summed all *normalized effective Z-scores* but we made a distinction between *normalized effective*  
 479 *Z-scores* where its path is connected to the upstream or the downstream side of reaction  $R$ . For clarity, let  
 480 us consider a direct substrate  $m$  of reaction  $R$ , which has a direct connection at the upstream side of the  
 481 reaction. Let us also assume that there is a path going from  $m$ , via other reactions, which ends at the  
 482 downstream side of the reaction. Since we have two paths, we have two *normalized effective Z-scores*; one  
 483 belonging to the direct connection, the other belonging to the longer path. Since the latter path is longer, its  
 484 *normalized effective Z-score* will be less than the *normalized effective Z-score* of the direct connection  
 485 (Equation 4). We aggregated all metabolite *normalized effective Z-scores* based on the *Z-score sign* and  
 486 connection to the reaction (downstream or upstream):

$$487 \quad E_{x,y}^R = \sum_{m \in \Omega_x^R} \sum_{p \in \Omega_y^R} \tilde{E}_{m,R,p} \quad 5)$$

488  
 489  
 490 with  $x \in \{\text{positive Z-score, negative Z-score}\}$ ,  $y \in \{\text{downstream, upstream}\}$ .  $\Omega_x^R$  indicates the set of  
 491 metabolites having a *Z-score sign* equal to  $x$  and  $\Omega_y^R$  indicates the set of paths from  $m$  to  $R$  which are  
 492 connected to the  $y$ -side of reaction  $R$  (downstream or upstream). Since reversible reactions lack a clear  
 493 defined up – and downstream side, we assigned one of each side to the up – or downstream side while  
 494 making sure that product/substrate information was conserved.

495  
 496 Finally, we defined the *deficient reaction score* for reaction  $R$  as:

$$497 \quad S_R = \begin{cases} (E_{+,up}^R - E_{-,up}^R) + (E_{-,down}^R - E_{+,down}^R) & \text{if reaction is irreversible} \\ |(E_{+,up}^R - E_{-,up}^R) + (E_{-,down}^R - E_{+,down}^R)| & \text{if reaction is reversible} \end{cases} \quad 6)$$

498  
 499  
 500 where we replaced ‘positive *Z-score*’ and ‘negative *Z-score*’ for the symbol ‘+’ and ‘-’, respectively. We  
 501 replaced ‘downstream’ and ‘upstream’ for ‘down’ and ‘up’, respectively. We observe that  $S_R$  increases for  
 502 net positive *normalized effective Z-scores* located at the upstream side of the reaction and for net negative  
 503 *normalized effective Z-scores* located at the downstream side of the reaction, while  $S_R$  decreases for the

504 opposite cases. When a reaction is reversible we decided to take the absolute value, arguing that we are  
505 interested in an imbalance of the net positive and negative *normalized effective Z-scores* across the reaction  
506 regardless of which side of the reaction these *normalized effective Z-scores* were positioned.

507  
508 We need to realize that some enzymes catalyze multiple (unique) reactions, which leads to a multiplicity of  
509 the  $S_R$  scores per enzyme and (potentially) shared reactions with other enzymes catalyzing the same  
510 reaction(s). In this study we dealt with this issue by taking the maximum occurring  $S_R$  score for each  
511 enzyme, even if that same  $S_R$  score was already assigned to another enzyme. Alternatively, we could have  
512 considered the use of another metric (other than the maximum) such as the average of all associated  $S_R$   
513 scores, but since some associated reactions were considered poor, this average score could affect the  
514 performance negatively.

515  
516 **Overall performance of Reaffect using bootstrapped AUC**

517 Annotation of metabolites in the metabolomics data was performed per batch, which resulted in an unequal  
518 number of annotations per batch. This difference also affected the number of unique enzymes on which  
519 ranking was based per patient (Figure 4, *Total number of enzymes*). To correct for this, we expressed the  
520 (absolute) rank in as a percentile by dividing by the total number of enzymes multiplied by 100%. The  
521 overall performance of *Reaffect* for a certain choice of  $(a, b, c)$  was measured by displaying the percentage  
522 (vertical axis) of the IEM patients having the percentile rank of the correct IEM within the top  $x$  (horizontal  
523 axis). Calculating the area under the curve (AUC) for this relationship gives a measure for the overall  
524 performance, since a higher AUC indicates that a larger percentage of the IEM patients have a lower rank  
525 (steeper increase of the curve). We used a bootstrap procedure where we selected 1000 times a random  
526 75% of the total IEM patients for which we calculated the AUC. By taking the 50<sup>th</sup> percentile of these 1000  
527 AUCs we obtained a more robust overall performance for each  $(a, b, c)$ .

528  
529 **MetPropagate and comparison with Reaffect**

530 We downloaded the weighted STRING network (v11) from <https://github.com/emmagraham/metPropagate>  
531 (07-08-2020). ME scores were calculated in the exact same manner as described by Linck et al. Using the  
532 same terminology, metabolites having  $|Z\text{-score}| > 1.5$  were considered as ‘differentially abundant  
533 metabolites’. ME scores were propagated using the Local and Global Consistency (LGC) algorithm with  
534 settings `max_iter=30` and `alpha=0.99`.

535  
536 To objectively compare *Reaffect* with *MetPropagate* we took several factors into account:



- 537 1) Only metabolites were included with (HMDB) identifiers in the pathways/modules used by *Reaffect*  
538 and which were also present in the gene-metabolite sets used by *MetPropagate*.
- 539 2) Before determining ranks, the propagated ME scores for every gene were assigned to the associated  
540 enzyme(s). We removed genes (and thus enzymes) which did not overlap in the output of both  
541 algorithms. Thus, both outputs contained the exact same number of unique enzymes on which  
542 ranking was performed.
- 543 3) The ranks for *MetPropagate* were calculated using the propagated ME scores on the enzyme level.  
544 Note that we took the maximum propagated ME score for an enzyme when more genes were  
545 associated with that enzyme. Similarly, the ranks for *Reaffect* were determined from the  $S_R$  scores  
546 (as described above).

547

#### 548 **CADD scores**

549 Variants called by GATK3 (see Method, *WES data*) were annotated with *CADD* scores from Genome build  
550 GRCh37/ hg19 v1.6 (<https://cadd.gs.washington.edu/download>) for both SNVs and InDels. In this study  
551 we used the *CADD* (Phred) scores in two manners: 1) ranking genes based solely on the maximum *CADD*  
552 score occurring in each gene and 2) ranking genes using the *deficient reaction score* ( $S_R$  score) from *Reaffect*  
553 combined with the *CADD* scores. Note, that only genes were included in this ranking for which a  $S_R$  score  
554 was determined and which were present in the WES data.

555

556 Gene ranking using *Reaffect* in combination with *CADD* scores was done as follow:

- 557 1) Per enzyme the maximum  $S_R$  score was determined for all associated reactions. For each enzyme, all  
558 associated genes were determined and the same maximum  $S_R$  score was assigned to these genes.
- 559 2) The maximum *CADD* (Phred) score per gene was determined.
- 560 3) The  $S_R$  score (step 1) was multiplied with the *CADD* score (Phred) for each gene.
- 561 4) Genes were ranked on their integrated score (step 3).

562

563 For a subset of the IEM patients included in this study the disease-causing variant was identified either  
564 using whole exome sequencing (WES), Sanger sequencing or using an SNP array. Since WES data was not  
565 available for most IEM patients where the disease-causing variant(s) is identified, we assumed that we  
566 could include these patients using 15 random WES backgrounds while inserting the known disease-causing  
567 variant in each background. Consequently, we obtained 15 different rankings for each disease-causing gene.  
568 We assumed that the average of these 15 rankings is a good estimate of the rank when a real WES  
569 background was used (Discussion).

570

## 571 **Excluded IEM patients which were initially measured**

572 Although some IEM patients were initially measured they were not included in this study, which had two  
573 main reasons. First, in some cases there was no (clear) associated reaction related to the metabolites known  
574 as biomarkers for that IEM, e.g. defects in cofactor metabolism. For example, we left out a patient with a  
575 mutation in the MMACHC gene, one with a mutation in the MOCS3 gene and two patients with glutaric  
576 acidemia type 2 (ETFDH, ETFA, ETFB). Secondly, since *Reafect* does not make a distinction between  
577 different compartments within the body or cell, the inclusion of enzymatic deficiencies related to transport  
578 proteins is complicated. In these transport reactions the metabolite itself does not change, only its location  
579 changes, and therefore build-up of these metabolites are expected only in certain parts of the body or cell (  
580 Discussion). For this reason, we were not able to include a few patients with lysinuric protein intolerance  
581 (SLC7A7), and a patient with organic cation transporter 2 deficiency (SLC22A5)

582

## 583 **Funding**

584 This work was funded by the Erasmus Medical Centre, department of Clinical Genetics.

585

## 586 **Conflicts of Interest**

587 All authors state that they have no conflict of interest to declare. None of the authors accepted any  
588 reimbursements, fees, or funds from any organization that may in any way gain or lose financially from the  
589 results of this study. The authors have not been employed by such an organization. The authors do not have  
590 any other conflict of interest.

591

## 592 **Author contribution**

593 The development of the methods was done by MB, MR and GR. RB performed all the experimental work,  
594 among which compound identification of the metabolomics data. MB developed the software and  
595 performed the computational experiments. WdV contributed in methods to analyze and process WES data.  
596 The interpretation of the results was done by MB, MR, HB and GR. The manuscript was written by MB,  
597 MR, HB and GR. SD, JL, HH and MW provided data and resources. The research was under supervision  
598 of GR.

599

## 600 **Acknowledgement**

601 We want to thank and acknowledge Professor Robert Hofstra for his support and Dr. Geert Geeven for his  
602 comments and feedback on the manuscript.

603

604 **Code availability**

605 *Reaffect* is available at <https://github.com/mbongaerts/Reaffect>

606

607

608 **Supplementary data**

609

610 **Supplement 1. Comparison of ranks IEM patients *Reaffect* versus *MetPropagate***

611

612

ACADM	27.16	2.01	BCKDH	52.5	0.37	IVD	59.07	3.15	PDHA1	15.2	3.56
ACADM	27.41	16.3	CBS	7.59	4.07	IVD <sub>a</sub>	66.73	3.17	PSAT1	33.66	21.39
ACADM	29.07	19.26	CBS	9.86	2.13	IVD <sub>b</sub>	59.53	2.53	PSAT1	35.84	12.08
ACADM	8.86	15.75	CBS	18.05	0.94	MANBA	79.17	93.56	TYMP	0.19	0.0
ACADM	5.74	21.3	CPS1	34.66	19.13	MCCC2	73.89	0.0	XDH	0.39	0.0
ACADM	35.19	15.19	CPS1	4.14	1.88	MLYCD	73.5	58.8			
ACADVL	10.88	0.38	CPT2	6.2	9.4	MTHFR	11.07	3.19			
ACADVL	61.51	21.08	CPT2	0.19	0.0	MVK	68.61	31.39			
ACAT1	30.17	1.35	CPT2	0.0	0.0	OAT	1.73	0.96			
ACAT1	32.59	1.21	FAH	45.66	3.7	OGDH	14.15	1.51			
ACSF3	65.16	15.35	FAH	72.47	5.06	OTC	33.85	12.96			
ACY1	13.33	0.0	GAMT	0.0	27.92	OTC	33.52	11.81			
ADSL	0.38	0.0	GCDH	89.83	88.29	OTC	9.62	6.6			
ARG1	2.32	0.0	GCDH	70.41	89.75	PAH	0.38	0.0			
ASL	1.33	3.24	GLDC	58.81	3.96	PAH	0.39	0.0			
ASL	0.58	0.0	HADHA	33.46	44.92	PAH	0.39	0.19			
ASL	1.29	0.37	HADHA	41.77	52.68	PAH	0.55	0.37			
ASS <sub>a</sub>	0.93	0.0	HGD	61.7	36.42	PAH	0.98	2.76			
ASS <sub>b</sub>	0.71	0.71	HGD	35.05	16.76	PCCA	1.38	0.79			
BCKDH	3.98	24.81	HMGCL	26.45	27.77	PCCA	47.59	2.59			
	Percentile rank for MetPropagate	Percentile rank for Reaffect		Percentile rank for MetPropagate	Percentile rank for Reaffect		Percentile rank for MetPropagate	Percentile rank for Reaffect		Percentile rank for MetPropagate	Percentile rank for Reaffect

613

614 Figure S1. Comparison of the percentile ranks between *Reaffect* and *MetPropagate* per IEM patient.

615


616 **Supplement 2. The effect of flipping the Z-score on IEM ranking performance**

617

618 To explore the importance of taking the biochemical directionality and the sign of the Z-scores into account,  
619 we flipped the sign for all Z-scores (in all patients), and used *Reaffect* to rank the enzymatic deficiencies  
620 (Figure S2). We observe that the AUC was reduced by 26%, and for the lower region of the performance  
621 curve (<10%), the partial AUC even dropped by 61%. These results underline the importance of including  
622 this information when considering IEM ranking algorithms. A detailed comparison between the ranks  
623 obtained from both approaches can be found in Figure S3.

624

625



626

627 Figure S2. A) Full performance curves for *Reaffect* and *Reaffect with flipped Z-score signs*. B) Percentile ranks <= 10%.

628

ACADM	1.71	8.38	BCKDH	4.19	2.62	HGD	36.23	73.73	PAH	0.0	99.82
ACADM	3.76	3.08	CBS	2.13	4.09	HGD	18.46	57.04	PAH	0.0	100.0
ACADM	0.36	6.87	CBS	3.76	9.4	HMGCL	0.36	4.99	PAH	0.54	99.82
ACADM	0.51	17.09	CBS	0.87	6.93	HPRT1	0.54	6.45	PAH	0.18	99.82
ACADM	3.59	6.15	CPS1	19.37	24.61	IVD	1.54	4.1	PAH	2.86	100.0
ACADM	1.53	21.56	CPS1	1.73	2.95	IVD <sub>a</sub>	3.16	7.81	PCCA	0.76	5.15
ACADVL	1.42	24.16	CPT2	0.0	0.0	IVD <sub>b</sub>	0.19	2.79	PCCA	2.39	12.82
ACADVL	0.18	10.7	CPT2	9.01	10.75	MANBA	0.0	100.0	PDHA1	3.92	27.63
ACAT1	1.11	46.2	CPT2	0.0	0.0	MCCC2	0.0	99.83	PSAT1	19.89	28.62
ACAT1	1.24	43.34	FAH	3.77	94.61	MLYCD	10.3	3.55	PSAT1	6.88	37.55
ACSF3	17.94	52.1	FAH	4.64	95.36	MMUT	0.0	13.61	TYMP	0.0	0.35
ACY1	0.0	0.0	GAMT	28.99	0.18	MMUT	7.89	26.88	XDH	0.0	2.61
ADSL	0.0	0.17	GCDH	0.18	100.0	MMUT	1.64	26.0			
ARG1	0.36	26.11	GCDH	0.53	100.0	MTHFR	3.03	47.95			
ASL	2.93	9.14	GLDC	1.01	36.97	MVK	31.89	98.79			
ASL	0.0	3.73	GLDC	2.52	20.0	OAT	0.88	0.88			
ASL	0.36	4.67	GLDC	4.09	37.17	OGDH	1.83	32.72			
ASS <sub>a</sub>	0.0	2.74	GLDC	2.86	11.93	OTC	13.32	7.46			
ASS <sub>b</sub>	0.0	13.97	HADHA	0.54	0.54	OTC	6.7	9.42			
BCKDH	0.36	22.26	HADHA	1.62	2.33	OTC	11.88	1.1			

Percentile rank for Reaffect
Percentile rank for Reaffect with flipped Z-score sign
Percentile rank for Reaffect
Percentile rank for Reaffect with flipped Z-score sign
Percentile rank for Reaffect
Percentile rank for Reaffect with flipped Z-score sign

629

630 Figure S3. Comparison of the percentile ranks between *Reaffect* and *Reaffect with flipped Z-score signs* per IEM patient. We clearly  
 631 observe the negative effect of reversing the sign of the Z-scores on ranking.


632

633



634 **Supplement 3. *CADD* scores for WES and pathogenic variants**

635



636

637 Figure S4. Each boxplot indicates the distribution of the *CADD* (Phred) scores for variants in metabolic genes obtained in 15  
638 random WES files. The last boxplot shows the *CADD* scores (Phred) for the disease-causing variants found in the IEM patients  
639 (Table 1).

640

641 **Supplement 4. Manually added reactions**

642

643 The KEGG pathways and modules were extended with some additional reactions (see Table S1) to increase

644 the overlap between metabolites present in the pathways/modules and metabolites measured in plasma.

645 Note, that a reaction is defined as a graph which also includes a reaction node.

646

647 Table S1. Manually added reactions. The second and fourth column indicate the directionality of the reaction. '<=>' indicates that

648 the reaction is reversible whereas '<=>' indicates the direction of an irreversible reaction. Note that these 'reactions' passes through

649 a reaction node (Reaction ID). Most reactions originate from Recon3D.

Metabolite 1		Reaction ID		Metabolite 2
3-Hydroxyppyruvic acid	=>	HPYRR2x	=>	Glyceric acid
2-Methylbutyrylglycine	<=>	RE2428M	<=>	2-Methylbutanoyl-CoA
2-Methylbutyrylglycine	<=>	RE2428M	<=>	Glycine
C16OH   3-Hydroxyhexadecanoylcarnitine	<=>	C16OHc	<=>	(S)-3-Hydroxyhexadecanoyl-CoA
3-Methylcrotonylglycine	<=>	RE2111M	<=>	3-Methylcrotonyl-CoA
3-Methylcrotonylglycine	<=>	RE2111M	<=>	Glycine
glnac-man	=>	B_MANNASEly	=>	N-Acetyl-D-glucosamine
glnac-man	=>	B_MANNASEly	=>	D-Mannose
C10   Decanoylcarnitine	<=>	C100CPT1	<=>	Decanoyl-CoA
Glycylproline	<=>	GLYPROPRO1c	<=>	Glycine
Glycylproline	<=>	GLYPROPRO1c	<=>	Proline
C6   Hexanoylcarnitine	<=>	C60CPT1	<=>	Hexanoyl-CoA
Homocysteine thiolactone	<=>	RE1933C	<=>	Homocysteine
Isobutyrylglycine	<=>	RE2429M	<=>	Glycine
Isobutyrylglycine	<=>	RE2429M	<=>	2-Methylpropanoyl-CoA
C5   Isovalerylcarnitine	<=>	C50CPT1	<=>	3-Methylbutanoyl-CoA
Isovalerylglycine	<=>	RE2427M	<=>	Glycine
Isovalerylglycine	<=>	RE2427M	<=>	3-Methylbutanoyl-CoA
Malonyl-CoA	=>	r0430	=>	C3DC   Malonylcarnitine
N-Acetylasparagine	<=>	RE2032M	<=>	Asparagine
C14   Tetradecanoylcarnitine	<=>	C140CPT1	<=>	Tetradecanoyl-CoA
C5:1   Tiglylcarnitine	<=>	C51CPT1	<=>	2-Methylbut-2-enoyl-CoA
Octanoyl-CoA	<=>	C80CPT1	<=>	C8   Octanoylcarnitine
Butanoyl-CoA	<=>	C40CPT1	<=>	C4   Butyrylcarnitine
Propanoyl-CoA	<=>	C30CPT1	<=>	C3   Propionylcarnitine
(2S,3S)-3-Hydroxy-2-methylbutanoyl-CoA	<=>	R_2M3HBUc	<=>	2-Methyl-3-hydroxybutyric acid
2-Methylbut-2-enoyl-CoA	<=>	R_TIGGLYc	<=>	Tiglylglycine
N-Acetylmethionine	<=>	RE2640C	<=>	Methionine
N-Acetylaniline	<=>	RE2642C	<=>	L-Alanine
Glutaryl-CoA	<=>	FAOXC5C5DCc	<=>	C5DC   Glutaryl carnitine
3-Methylglutaconyl-CoA	<=>	3mgcoac61dcmgcrn	<=>	C6:1DC   3-Methylglutaconylcarnitine
3-Methylglutaconyl-CoA	<=>	MGCHrm	<=>	(S)-3-Hydroxy-3-methylglutaryl-CoA
(S)-3-Hydroxy-3-methylglutaryl-CoA	<=>	hmgcoac6dcmgcrn	<=>	C6DC   3-Methylglutaryl carnitine
3-Hydroxyisovaleryl-CoA	<=>	C059983ivcrn	<=>	C5OH   3-Hydroxyisovalerylcarnitine
3-Hydroxyisovaleryl-CoA	<=>	C059983CE2028	<=>	3-Hydroxyisovaleric acid
Adenylosuccinate	=>	C03794succinyladenosine	=>	Succinyladenosine
L-Aspartate	=>	ASPCTr	=>	N-Carbamoyl-L-aspartate
Carbamoylphosphate	=>	ASPCTr	=>	N-Carbamoyl-L-aspartate
Dihydroorotic acid	=>	DHORTS	=>	N-Carbamoyl-L-aspartate
Dihydroorotic acid	<=>	DHORD9	<=>	Orotic acid
Malonate	=>	C00383malcoa	=>	Malonyl-CoA
Malonyl-CoA	=>	MCDm	=>	Acetyl-CoA
7-Dehydrocholesterol	=>	HMR_2114	=>	Vitamine D3
Cholesterol sulfate	<=>	RE1100L	<=>	Cholesterol

650

651


652

653 **Supplement 5. Optimizing the decay factors while excluding the samples with an identified disease-**  
654 **causing variant**

655

656 In this study we used all 72 IEM patients samples to optimize the decay factors and to evaluate *Reaffect*'s  
657 performance on IEM/gene ranking. To support our findings, especially for the results where we integrated  
658 the *deficient reaction scores* with *CADD* scores (Table 1), we optimized the decay factors on 44/72 samples  
659 where we excluded the patients with an identified disease-causing variant. We used the same bootstrap  
660 procedure for determining the optimal values for the decay factors (Methods). We found that the optimum  
661 was at  $a = 0.85$ ,  $b = 0.45$ ,  $c = 0.75$  (100%), and the second best combination was  $a = 0.85$ ,  $b = 0.35$ ,  $c =$   
662  $0.75$  (99.96%) (Figure S5). However, we also observe that the optimum is wider and less well-defined as  
663 the one observed in Figure 2.

664



665


666 Figure S5. **A)** Bootstrapped AUCs (Methods) for given combinations of  $(a,b,c)$  indicating the performance of *Reaffect*. The colors  
667 indicate the percentage of the maximum obtained AUC. For this analysis we used 44/72 IEM patients samples, where we excluded  
668 the patients with an identified disease-causing variant. **B)** Contour plot of the (cubic interpolated) bootstrapped AUCs while fixing  
669  $c=0.75$  and varying  $a$  and  $b$ . The contour levels indicate the percentage of the maximum AUC reached at  $a = 0.85$ ,  $b = 0.45$ ,  $c =$   
670  $0.75$ .

671

## 672 Supplement 6. Contribution of subtle metabolite Z-scores on IEM ranking

673  
674 We explored the contribution of more subtle metabolite Z-scores to the IEM ranking performance of  
675 *Reaffect*. This was investigated by creating performance curves for various Z-score cutoffs, where we  
676 included only metabolite Z-scores for which  $|Z\text{-score}| < \text{cutoff}$  (Figure S6A) or  $|Z\text{-score}| > \text{cutoff}$  (Figure  
677 S6B). These results show that for decreasing cutoff values and  $|Z\text{-score}| < \text{cutoff}$ , the overall performance  
678 on IEM ranking also declines. This can be understood by realizing that for decreasing cutoff values, also  
679 more informative (disease-related) metabolites are excluded. More importantly, we observe that even for  
680 the lower cutoff values the overall performance is still positive (above the diagonal line), suggesting that  
681 more subtle metabolite Z-scores also contribute to IEM ranking. The same conclusion can be drawn from  
682 the experiment where we included only metabolites having a  $|Z\text{-score}| > \text{cutoff}$ . When increasing the cutoff  
683 values, we observe that the IEM ranking performance also decreases. Since in these cases only more  
684 extreme Z-scores are available for ranking, we conclude that more subtle metabolite Z-scores normally also  
685 contribute to IEM ranking.

686



687  
688 Figure S6. **A)** Full performance curves for *Reaffect* for various Z-score cutoff values, and  $|Z\text{-score}| < \text{cutoff}$ . Cutoff values are  
689 indicated by the legend. **B)** Full performance curves for *Reaffect* for various Z-score cutoff values, and  $|Z\text{-score}| > \text{cutoff}$ .

690

## 691 **References**

- 692 Alaimo, J. T. et al., 2020. Integrated analysis of metabolomic profiling and exome data supplements  
693 sequence variant interpretation, classification, and diagnosis. *Genetics in Medicine*, 5.
- 694 Baumgartner, C. et al., 2004. Supervised machine learning techniques for the classification of metabolic  
695 disorders in newborns. *Bioinformatics*, 6, Volume 20, p. 2985–2996.
- 696 Bongaerts, M. et al., 2020. Using Out-of-Batch Reference Populations to Improve Untargeted  
697 Metabolomics for Screening Inborn Errors of Metabolism. *Metabolites*, 12, Volume 11, p. 8.
- 698 Bonte, R. et al., 2019. Untargeted Metabolomics-Based Screening Method for Inborn Errors of  
699 Metabolism using Semi-Automatic Sample Preparation with an UHPLC- Orbitrap-MS Platform.  
700 *Metabolites*, 11, Volume 9, p. 289.
- 701 Haijes, H. A. et al., 2020. Untargeted Metabolomics for Metabolic Diagnostic Screening with Automated  
702 Data Interpretation Using a Knowledge-Based Algorithm. *International Journal of Molecular Sciences*, 2,  
703 Volume 21, p. 979.
- 704 Kanehisa, M., 2000. KEGG: Kyoto Encyclopedia of Genes and Genomes. *Nucleic Acids Research*, 1,  
705 Volume 28, p. 27–30.
- 706 Kerkhofs, M. H. P. M. et al., 2020. Cross-Omics: Integrating Genomics with Metabolomics in Clinical  
707 Diagnostics. *Metabolites*, 5, Volume 10, p. 206.
- 708 Lee, J. J. Y. et al., 2017. Knowledge base and mini-expert platform for the diagnosis of inborn errors of  
709 metabolism. *Genetics in Medicine*, 7, Volume 20, p. 151–158.
- 710 Li, H. & Durbin, R., 2009. Fast and accurate short read alignment with Burrows-Wheeler transform.  
711 *Bioinformatics*, 5, Volume 25, p. 1754–1760.
- 712 Linck, E. J. G. et al., 2020. metPropagate: network-guided propagation of metabolomic information for  
713 prioritization of metabolic disease genes. *npj Genomic Medicine*, 7, Volume 5.
- 714 McKenna, A. et al., 2010. The Genome Analysis Toolkit: A MapReduce framework for analyzing next-  
715 generation DNA sequencing data. *Genome Research*, 7, Volume 20, p. 1297–1303.
- 716 Messa, G. M. et al., 2020. A Siamese neural network model for the prioritization of metabolic disorders  
717 by integrating real and simulated data. *Bioinformatics*, 12, Volume 36, p. i787–i794.
- 718 Noronha, A. et al., 2018. The Virtual Metabolic Human database: integrating human and gut microbiome  
719 metabolism with nutrition and disease. *Nucleic Acids Research*, 10, Volume 47, p. D614–D624.
- 720 Pirhaji, L. et al., 2016. Revealing disease-associated pathways by network integration of untargeted  
721 metabolomics. *Nature Methods*, 8, Volume 13, p. 770–776.
- 722 Pronicka, E. et al., 2016. New perspective in diagnostics of mitochondrial disorders: two years'  
723 experience with whole-exome sequencing at a national paediatric centre. *Journal of Translational*  
724 *Medicine*, 6, Volume 14.
- 725 Rentzsch, P. et al., 2018. CADD: predicting the deleteriousness of variants throughout the human  
726 genome. *Nucleic Acids Research*, 10, Volume 47, p. D886–D894.

- 727 Stavropoulos, D. J. et al., 2016. Whole-genome sequencing expands diagnostic utility and improves  
728 clinical management in paediatric medicine. *npj Genomic Medicine*, 1. Volume 1.
- 729 Thiele, I. et al., 2013. A community-driven global reconstruction of human metabolism. *Nature*  
730 *Biotechnology*, 3, Volume 31, p. 419–425.
- 731 Wang, K., Li, M. & Hakonarson, H., 2010. ANNOVAR: functional annotation of genetic variants from  
732 high-throughput sequencing data. *Nucleic Acids Research*, 7, Volume 38, p. e164–e164.
- 733 Waters, D. et al., 2018. Global birth prevalence and mortality from inborn errors of metabolism: a  
734 systematic analysis of the evidence. *Journal of Global Health*, 11. Volume 8.
- 735 Wright, C. F., FitzPatrick, D. R. & Firth, H. V., 2018. Paediatric genomics: diagnosing rare disease in  
736 children. *Nature Reviews Genetics*, 2, Volume 19, p. 253–268.
- 737
- 738